125 related articles for article (PubMed ID: 11422606)
1. Population pharmacokinetic modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: implications for dosage.
Bondareva IB; Sokolov AV; Tischenkova IF; Jelliffe RW
J Clin Pharm Ther; 2001 Jun; 26(3):213-23. PubMed ID: 11422606
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage.
Bondareva IB; Jelliffe RW; Gusev EI; Guekht AB; Melikyan EG; Belousov YB
J Clin Pharm Ther; 2006 Jun; 31(3):211-21. PubMed ID: 16789986
[TBL] [Abstract][Full Text] [Related]
3. Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy.
Bondareva IB; Jelliffe RW; Andreeva OV; Bondareva KI
J Clin Pharm Ther; 2011 Oct; 36(5):625-36. PubMed ID: 21062333
[TBL] [Abstract][Full Text] [Related]
4. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
Carlsson KC; Hoem NO; Glauser T; Vinks AA
Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
[TBL] [Abstract][Full Text] [Related]
5. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.
Bondareva IB; Jelliffe RW; Sokolov AV; Tischenkova IF
J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399
[TBL] [Abstract][Full Text] [Related]
6. Predictive capacity of carbamazepine pharmacokinetic parameters in a Portuguese outpatient population.
Falcão AC; de Almeida AM; Leitão F; Santos J; Sales F; Caramona MM
Ther Drug Monit; 1999 Apr; 21(2):224-30. PubMed ID: 10217344
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients.
Deleu D; Aarons L; Ahmed IA
Eur J Clin Pharmacol; 2001 Jun; 57(3):243-8. PubMed ID: 11497340
[TBL] [Abstract][Full Text] [Related]
9. Bayesian estimation of six different sets of carbamazepine pharmacokinetic parameters in Egyptian adult epileptic patients.
EL Desoky ES; Kandil MR
Pharmacol Res; 2002 Feb; 45(2):113-8. PubMed ID: 11846622
[TBL] [Abstract][Full Text] [Related]
10. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data.
Battino D; Croci D; Rossini A; Messina S; Mamoli D; Perucca E
Epilepsia; 2003 Jul; 44(7):923-9. PubMed ID: 12823575
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing carbamazepine pharmacokinetics in children and adults: population pharmacokinetic analysis.
Milovanovic JR; Jankovic SM
Int J Clin Pharmacol Ther; 2011 Jul; 49(7):428-36. PubMed ID: 21726493
[TBL] [Abstract][Full Text] [Related]
12. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
[TBL] [Abstract][Full Text] [Related]
13. Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication.
Kong ST; Lim SH; Chan E; Ho PC
J Clin Pharmacol; 2014 Feb; 54(2):225-33. PubMed ID: 23996245
[TBL] [Abstract][Full Text] [Related]
14. Kinetic profile of carbamazepine in an adult Portuguese outpatient population.
Almeida AM; Falcão AC; Sales F; Leitão F; Santos J; Costa IM; Caramona MM
J Clin Pharm Ther; 1998 Aug; 23(4):315-21. PubMed ID: 9867316
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice.
Johannessen Landmark C; Svendsen T; Dinarevic J; Kufaas RF; Reimers A; Brodtkorb E; Baftiu A; Burns ML; Johannessen SI
Ther Drug Monit; 2016 Aug; 38(4):499-505. PubMed ID: 27414974
[TBL] [Abstract][Full Text] [Related]
16. Estimation of population pharmacokinetics for carbamazepine in Malaysian patients using the OPT computer program.
Ismail R; Rahman AF
J Clin Pharm Ther; 1993 Feb; 18(1):55-8. PubMed ID: 8473361
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients.
Jankovic SM; Jovanovic D; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2008 Nov; 30(9):707-13. PubMed ID: 19229380
[TBL] [Abstract][Full Text] [Related]
18. Carbamazepine and lamotrigine plasma concentrations in epileptic patients during optimising therapy.
Krasniqi S; Neziri B; Islami H; Bauer S
Med Arh; 2010; 64(2):80-3. PubMed ID: 20514770
[TBL] [Abstract][Full Text] [Related]
19. Predictions of carbamazepine concentrations using a Bayesian program (PKS System, Abbott): a retrospective evaluation in an outpatient population.
Gaulier JM; Boulieu R; Fischer C; Mauguiere F
J Pharm Pharmacol; 1997 Jul; 49(7):734-6. PubMed ID: 9255721
[TBL] [Abstract][Full Text] [Related]
20. Comparison between the Cobas Integra immunoassay and high-performance liquid chromatography for therapeutic monitoring of carbamazepine.
Hermida J; Bóveda MD; Vadillo FJ; Tutor JC
Clin Biochem; 2002 May; 35(3):251-4. PubMed ID: 12074835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
